Relugolix
Combination
Tablet

Relugolix Combination Tablet consists of relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg. Relugolix Combination Tablet is under investigation for the prevention of pregnancy in women with uterine fibroids or endometriosis.

Relugolix Combination Tablet is not
approved by the FDA in the
prevention of pregnancy.

Combination Therapy Approach for Women’s Health

We are developing relugolix 40 mg in combination with estradiol (1.0 mg) and a progestin (0.5 mg norethindrone acetate). Estradiol and progestins are hormones similar to those naturally-occurring in the body. Low-estrogen levels can weaken bone health and cause unwanted side effects such as hot flashes. Low doses of estradiol and progestins help offset these effects. We are investigating whether this combination maintains estrogen in the low normal range to balance the potential benefits of relugolix, while also maintaining bone health and mitigating the side effects that can result from a low-estrogen state.

Monotherapy Approach for Prostate Cancer

We are developing relugolix 120 mg following a single 360 mg loading dose. We are investigating whether this monotherapy decreases testosterone to low levels.

Relugolix
Combination
Tablet

How it works

Combination Therapy Approach for Women’s Health

Monotherapy Approach for Prostate Cancer

Recent News and Presentations

10 Mar 2023

26 Jan 2023

16 Nov 2022